Best known for its repositionable Trinity TAVI system, Germany’s Transcatheter Technologies GmbH is expanding its product family to include a transcatheter mitral valve implantation (TMVI) version, tagged Tresillo.
Transcatheter Technologies’ Trinity aortic valve prostheses and Tresillo mitral valve prosthesis are comprised of a bovine pericardium valve mounted on a self-expanding Nitinol frame. The unique features of Trinity (TAVI) and Tresillo (TMVI) enable controlled positioning and repositioning.
The company explains that its biological valve prostheses are protected during folding of the stent. This Zero Pressure Crimping™ is designed to improve valve durability and broaden the application of transcatheter valve implantations across a larger patient population
Transcatheter mitral valve implantation is the next frontier for structural heart therapy. It is expected to revolutionize the way of treating mitral valve insufficiency. Approximately 3% of the population older than 60 years is suffering from symptomatic mitral valve regurgitation and may benefit from this interventional procedure while avoiding open-heart surgery.
“Per plan, we are expanding our platform technology to comprise a transfemoral and transapical Trinity TAVI system as well as a transfemoral Tresillo mitral valve implantation system. These three systems all share the same features. The premounted, valved stent is folded without the need of an outer sheath, thereby enabling precision controlled positioning and also allowing for repositioning if needed. This feature is most certainly unique to Trinity and Tresillo,” said Wolfgang Goetz, M.D., Ph.D., CEO.
“While we are very pleased with our product development variety and timelines,” added Dr. Goetz, “we are planning to further expand our pipeline of interventional innovations that are designed not only to be simpler to use but also facilitate superior patient safety and outcomes.”
Source: Business Wire